Provision Language
3. RIGHT TO SUB-LICENSE TO MPP LICENSEES
[…]
3.4. MPP may grant sub-licences and may disclose to MPP Licensees only such of the Confidential Information as is necessary for the exercise of the rights sub-licensed, subject in each case to the following conditions:
[…]
3.4.2. For the purposes of this Agreement and any Development and Commercialisation Agreement, the “Specific Access Commitments” are:
[…]
d. “QA Commitment” – the Final Product will be developed in accordance with appropriate quality standards and Commercialisation Partners will seek, when appropriate, approval or a positive recommendation for the Final Product from the WHO Prequalification Programme (PQ), Global Fund/Unitaid Expert Review Panel (ERP), US FDA and/or another WHO Listed Regulatory Authority as agreed between Unitaid, MedinCell and MPP.
Schedule 4. Commercialisation Agreement Term Sheet
2. Access Commitments: […] For the purposes of the Commercialisation Agreement, the “Specific Access Commitments” are:
[…]
d. “QA Commitment” – the Final Product will be developed in accordance with appropriate quality standards and Commercialisation Partners will seek, when appropriate, approval or a positive recommendation for the Final Product from the WHO Prequalification Programme (PQ), Global Fund/Unitaid Expert Review Panel (ERP), US FDA and/or another WHO Listed Regulatory Authority as agreed between Unitaid and MedinCell.